A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer

Jakob Eberhard; Alexander Gaber; Sakarias Wangefjord; Björn Nodin; M Uhlén; Kajsa Ericson Lindquist; Karin Jirström

doi:10.1038/bjc.2012.34

A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer

Jakob Eberhard, Alexander Gaber, Sakarias Wangefjord, Björn Nodin, M Uhlén, Kajsa Ericson Lindquist, Karin Jirström

KTH Royal Institute of Technology

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of colorectal cancer (CRC), and loss of SATB2 has been linked to poor survival from the disease. In this study, we validated the prognostic ability of SATB2 expression in a large, prospective CRC cohort.

METHODS: Immunohistochemical SATB2 expression was assessed in 527 incident CRC cases from the Malmö Diet and Cancer Study. Kaplan-Meier analysis and Cox proportional hazards modelling were used to explore the impact of SATB2 expression on cancer-specific survival (CSS) and overall survival (OS).

RESULTS: High SATB2 expression was associated with a prolonged CSS in the full cohort (hazard ratio (HR)=0.61; 95% CI 0.41-0.92) and in colon cancer (HR=0.39; 95% CI 0.20-0.75), remaining significant in multivariable analysis of colon cancer (HR=0.49; 95% CI 0.25-0.96), with similar findings for OS. In curatively resected stage III-IV patients, a significant benefit from adjuvant and/or neoadjuvant therapy was observed for SATB2 high tumours (P(interaction)=0.037 for OS) and high SATB2 expression in rectal cancer correlated with an enhanced effect of neoadjuvant therapy (P(interaction)=0.033 for OS).

CONCLUSION: High SATB2 expression is an independent marker of good prognosis in colon cancer and may modulate sensitivity to chemotherapy and radiation.

Original language	English
Pages (from-to)	931-938
Number of pages	8
Journal	British Journal of Cancer
Volume	106
Issue number	5
DOIs	https://doi.org/10.1038/bjc.2012.34
Publication status	Published - 2012 Feb 28

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Pathology, (Lund) (013030000)

Subject classification (UKÄ)

Cancer and Oncology

Free keywords

Aged
Aged, 80 and over
Biomarkers, Tumor
Cohort Studies
Colorectal Neoplasms
Gene Expression Regulation, Neoplastic
Humans
Kaplan-Meier Estimate
Matrix Attachment Region Binding Proteins
Neoplasm Staging
Prognosis
Proportional Hazards Models
Transcription Factors
Treatment Outcome
Journal Article
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2012.34

http://www.ncbi.nlm.nih.gov/pubmed/22333599?dopt=Abstract

Cite this

@article{e5eae6a75dc04914bfef2611d731fc19,

title = "A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer",

abstract = "BACKGROUND: Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of colorectal cancer (CRC), and loss of SATB2 has been linked to poor survival from the disease. In this study, we validated the prognostic ability of SATB2 expression in a large, prospective CRC cohort.METHODS: Immunohistochemical SATB2 expression was assessed in 527 incident CRC cases from the Malm{\"o} Diet and Cancer Study. Kaplan-Meier analysis and Cox proportional hazards modelling were used to explore the impact of SATB2 expression on cancer-specific survival (CSS) and overall survival (OS).RESULTS: High SATB2 expression was associated with a prolonged CSS in the full cohort (hazard ratio (HR)=0.61; 95% CI 0.41-0.92) and in colon cancer (HR=0.39; 95% CI 0.20-0.75), remaining significant in multivariable analysis of colon cancer (HR=0.49; 95% CI 0.25-0.96), with similar findings for OS. In curatively resected stage III-IV patients, a significant benefit from adjuvant and/or neoadjuvant therapy was observed for SATB2 high tumours (P(interaction)=0.037 for OS) and high SATB2 expression in rectal cancer correlated with an enhanced effect of neoadjuvant therapy (P(interaction)=0.033 for OS).CONCLUSION: High SATB2 expression is an independent marker of good prognosis in colon cancer and may modulate sensitivity to chemotherapy and radiation.",

keywords = "Aged, Aged, 80 and over, Biomarkers, Tumor, Cohort Studies, Colorectal Neoplasms, Gene Expression Regulation, Neoplastic, Humans, Kaplan-Meier Estimate, Matrix Attachment Region Binding Proteins, Neoplasm Staging, Prognosis, Proportional Hazards Models, Transcription Factors, Treatment Outcome, Journal Article, Research Support, Non-U.S. Gov't",

author = "Jakob Eberhard and Alexander Gaber and Sakarias Wangefjord and Bj{\"o}rn Nodin and M Uhl{\'e}n and {Ericson Lindquist}, Kajsa and Karin Jirstr{\"o}m",

note = "The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology, (Lund) (013030000)",

year = "2012",

month = feb,

day = "28",

doi = "10.1038/bjc.2012.34",

language = "English",

volume = "106",

pages = "931--938",

journal = "British Journal of Cancer",

issn = "1532-1827",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer

AU - Eberhard, Jakob

AU - Gaber, Alexander

AU - Wangefjord, Sakarias

AU - Nodin, Björn

AU - Uhlén, M

AU - Ericson Lindquist, Kajsa

AU - Jirström, Karin

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology, (Lund) (013030000)

PY - 2012/2/28

Y1 - 2012/2/28

N2 - BACKGROUND: Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of colorectal cancer (CRC), and loss of SATB2 has been linked to poor survival from the disease. In this study, we validated the prognostic ability of SATB2 expression in a large, prospective CRC cohort.METHODS: Immunohistochemical SATB2 expression was assessed in 527 incident CRC cases from the Malmö Diet and Cancer Study. Kaplan-Meier analysis and Cox proportional hazards modelling were used to explore the impact of SATB2 expression on cancer-specific survival (CSS) and overall survival (OS).RESULTS: High SATB2 expression was associated with a prolonged CSS in the full cohort (hazard ratio (HR)=0.61; 95% CI 0.41-0.92) and in colon cancer (HR=0.39; 95% CI 0.20-0.75), remaining significant in multivariable analysis of colon cancer (HR=0.49; 95% CI 0.25-0.96), with similar findings for OS. In curatively resected stage III-IV patients, a significant benefit from adjuvant and/or neoadjuvant therapy was observed for SATB2 high tumours (P(interaction)=0.037 for OS) and high SATB2 expression in rectal cancer correlated with an enhanced effect of neoadjuvant therapy (P(interaction)=0.033 for OS).CONCLUSION: High SATB2 expression is an independent marker of good prognosis in colon cancer and may modulate sensitivity to chemotherapy and radiation.

AB - BACKGROUND: Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of colorectal cancer (CRC), and loss of SATB2 has been linked to poor survival from the disease. In this study, we validated the prognostic ability of SATB2 expression in a large, prospective CRC cohort.METHODS: Immunohistochemical SATB2 expression was assessed in 527 incident CRC cases from the Malmö Diet and Cancer Study. Kaplan-Meier analysis and Cox proportional hazards modelling were used to explore the impact of SATB2 expression on cancer-specific survival (CSS) and overall survival (OS).RESULTS: High SATB2 expression was associated with a prolonged CSS in the full cohort (hazard ratio (HR)=0.61; 95% CI 0.41-0.92) and in colon cancer (HR=0.39; 95% CI 0.20-0.75), remaining significant in multivariable analysis of colon cancer (HR=0.49; 95% CI 0.25-0.96), with similar findings for OS. In curatively resected stage III-IV patients, a significant benefit from adjuvant and/or neoadjuvant therapy was observed for SATB2 high tumours (P(interaction)=0.037 for OS) and high SATB2 expression in rectal cancer correlated with an enhanced effect of neoadjuvant therapy (P(interaction)=0.033 for OS).CONCLUSION: High SATB2 expression is an independent marker of good prognosis in colon cancer and may modulate sensitivity to chemotherapy and radiation.

KW - Aged

KW - Aged, 80 and over

KW - Biomarkers, Tumor

KW - Cohort Studies

KW - Colorectal Neoplasms

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Kaplan-Meier Estimate

KW - Matrix Attachment Region Binding Proteins

KW - Neoplasm Staging

KW - Prognosis

KW - Proportional Hazards Models

KW - Transcription Factors

KW - Treatment Outcome

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1038/bjc.2012.34

DO - 10.1038/bjc.2012.34

M3 - Article

C2 - 22333599

SN - 1532-1827

VL - 106

SP - 931

EP - 938

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 5

ER -

A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer

Abstract

Bibliographical note

Subject classification (UKÄ)

Free keywords

UN SDGs

Access to Document

Fingerprint

Cite this